Larvol Delta - Characterization-and-preclinical-evaluation-of-the-cGMP-grade-DNA-based-vaccine-AV1959D-to-enter-the-firstinhuman-clinical-trials

AV-1959D - Capo Therap

http://www.ncbi.nlm.nih.gov/pubmed/32119976

Mar 3, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next